서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 12 of 12

Issue DateTitle / Author(s) / CitationFileAltmetrics
2014-08
Effect of PD-1-deficiency on the development of CD8 T cell response for a minor histocompatibility antigen, H60
view file
2015-10
High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy
DOI
2018-02
Radiation-induced change of PD-1/PD-L1 immune checkpoint in mouse and human colorectal cancer models
view file
2018-02
Oral angiogenesis inhibitor LHbisD4 synergistically enhances anti-cancer therapy by combination with αPD-1 antibody
view file
2018-03
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
DOI
2018-09
Activation of NKT cells in an anti-PD-1-resistant tumor model enhances antitumor immunity by reinvigorating exhausted CD8 T cells
DOI
2019-01
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
view fileDOI
2019-03
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
view fileDOI
2020-01
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
DOI
2020-03
Reduction of circulating innate lymphoid cell progenitors results in impaired cytokine production by innate lymphoid cells in patients with lupus nephritis
DOI
2021-02
The combination of photodynamic therapy using phthalocyanin/albumin nano complex with immunotherapy in breast cancer model.
link
2021-04
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
DOI
1